|
1
|
Elbahesh E, Patel N and Tabbara IA:
Treatment of acute promyelocytic leukemia. Anticancer Res.
34:1507–1517. 2014.PubMed/NCBI
|
|
2
|
Lynch RC and Medeiros BC: Chemotherapy
options for previously untreated acute myeloid leukemia. Expert
Opin Pharmacother. 16:2149–2162. 2015.PubMed/NCBI
|
|
3
|
Tallman MS, Gilliland DG and Rowe JM: Drug
therapy for acute myeloid leukemia. Blood. 106:1154–1163. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chomel JC, Bonnet ML, Sorel N, Bertrand A,
Meunier MC, Fichelson S, Melkus M, Bennaceur-Griscelli A, Guilhot F
and Turhan AG: Leukemic stem cell persistence in chronic myeloid
leukemia patients with sustained undetectable molecular residual
disease. Blood. 118:3657–3660. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schrappe M, Valsecchi MG, Bartram CR,
Schrauder A, Panzer-Grümayer R, Möricke A, Parasole R, Zimmermann
M, Dworzak M, Buldini B, et al: Late MRD response determines
relapse risk overall and in subsets of childhood T-cell ALL:
Results of the AIEOP-BFM-ALL 2000 study. Blood. 118:2077–2084.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oran B and de Lima M: Prevention and
treatment of acute myeloid leukemia relapse after allogeneic stem
cell transplantation. Curr Opin Hematol. 18:388–394. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Campana D: Progress of minimal residual
disease studies in childhood acute leukemia. Curr Hematol Malig
Rep. 5:169–176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ravindranath Y: Recent advances in
pediatric acute lymphoblastic and myeloid leukemia. Curr Opin
Oncol. 15:23–35. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rowe JM and Goldstone AH: How I treat
acute lymphocytic leukemia in adults. Blood. 110:2268–2275. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guzman ML, Neering SJ, Upchurch D, Grimes
B, Howard DS, Rizzieri DA, Luger SM and Jordan CT: Nuclear
factor-kappaB is constitutively activated in primitive human acute
myelogenous leukemia cells. Blood. 98:2301–2307. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Y, Krivtsov AV, Sinha AU, North TE,
Goessling W, Feng Z, Zon LI and Armstrong SA: The Wnt/beta-catenin
pathway is required for the development of leukemia stem cells in
AML. Science. 327:1650–1653. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bellavia D, Campese AF, Alesse E, Vacca A,
Felli MP, Balestri A, Stoppacciaro A, Tiveron C, Tatangelo L,
Giovarelli M, et al: Constitutive activation of NF-kappaB and
T-cell leukemia/lymphoma in Notch3 transgenic mice. Embo J.
19:3337–3348. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hadian K and Krappmann D: Signals from the
nucleus: Activation of NF-kappaB by cytosolic ATM in the DNA damage
response. Sci Signal. 4:pe22011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miyamoto S: Nuclear initiated NF-κB
signaling: NEMO and ATM take center stage. Cell Res. 21:116–130.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu ZH and Miyamoto S: Induction of a
pro-apoptotic ATM-NF-kappaB pathway and its repression by ATR in
response to replication stress. EMBO J. 27:1963–1973. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sakurai T, Maeda S, Chang L and Karin M:
Loss of hepatic NF-kappa B activity enhances chemical
hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1
activation. Proc Natl Acad Sci USA. 103:10544–10551. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Igarashi H, Baba Y, Nagai Y, Jimi E, Ghosh
S and Kincade PW: NF-kappaB is dispensable for normal lymphocyte
development in bone marrow but required for protection of
progenitors from TNFalpha. Int Immunol. 18:653–659. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wullaert A, van Loo G, Heyninck K and
Beyaert R: Hepatic tumor necrosis factor signaling and nuclear
factor-kappaB: Effects on liver homeostasis and beyond. Endocr Rev.
28:365–386. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oguma K, Oshima H and Oshima M:
Inflammation, tumor necrosis factor and Wnt promotion in gastric
cancer development. Future Oncol. 6:515–526. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Balkwill F: Tumour necrosis factor and
cancer. Nat Rev Cancer. 9:361–371. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Geisler F, Algül H, Paxian S and Schmid
RM: Genetic inactivation of RelA/p65 sensitizes adult mouse
hepatocytes to TNF-induced apoptosis in vivo and in vitro.
Gastroenterology. 132:2489–2503. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hatano E: Tumor necrosis factor signaling
in hepatocyte apoptosis. J Gastroenterol Hepatol. 22(Suppl 1):
S43–S44. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Quante M and Wang TC: Inflammation and
stem cells in gastrointestinal carcinogenesis. Physiology
(Bethesda). 23:350–359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee YR, Yu HN, Noh EM, Youn HJ, Song EK,
Han MK, Park CS, Kim BS, Park YS, Park BK, et al: TNF-alpha
upregulates PTEN via NF-kappaB signaling pathways in human leukemic
cells. Exp Mol Med. 39:121–127. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kagoya Y, Yoshimi A, Kataoka K, Nakagawa
M, Kumano K, Arai S, Kobayashi H, Saito T, Iwakura Y and Kurokawa
M: Positive feedback between NF-κB and TNF-α promotes
leukemia-initiating cell capacity. J Clin Invest. 124:528–542.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Morotti A, Cilloni D, Pautasso M, Messa F,
Arruga F, Defilippi I, Carturan S, Catalano R, Rosso V, Chiarenza
A, et al: NF-κB inhibition as a strategy to enhance
etoposide-induced apoptosis in K562 cell line. Am J Hematol.
81:938–945. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rivas MA, Carnevale RP, Proietti CJ,
Rosemblit C, Beguelin W, Salatino M, Charreau EH, Frahm I, Sapia S,
Brouckaert P, et al: TNF alpha acting on TNFR1 promotes breast
cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent
pathways. Exp Cell Res. 314:509–529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mueller T, Voigt W, Simon H, Fruehauf A,
Bulankin A, Grothey A and Schmoll HJ: Failure of activation of
caspase-9 induces a higher threshold for apoptosis and cisplatin
resistance in testicular cancer. Cancer Res. 63:513–521.
2003.PubMed/NCBI
|
|
30
|
Giuliani C, Napolitano G, Bucci I, Montani
V and Monaco F: Nf-κB transcription factor: Role in the
pathogenesis of inflammatory, autoimmune, and neoplastic diseases
and therapy implications. Clin Ter. 152:249–253. 2001.(In Italian).
PubMed/NCBI
|
|
31
|
Baud V and Jacque E: The alternative NF-κB
activation pathway and cancer: Friend or foe? Med Sci (Paris).
24:1083–1088. 2008.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Moitreyee CK, Suraksha A and Swarup AS:
Potential role of NF-κB and RXR beta like proteins in interferon
induced HLA class I and beta globin gene transcription in K562
erythroleukaemia cells. Mol Cell Biochem. 178:103–112. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kamieńska E, Ociepa T, Wysocki M, Kurylak
A, Matysiak M, Urasiński T, Urasińska E and Domagała W: Activation
of NF-κB in leukemic cells in response to initial prednisone
therapy in children with acute lymphoblastic leukaemia: Relation to
other prognostic factors. Pol J Pathol. 62:5–11. 2011.PubMed/NCBI
|
|
34
|
Cosimo E, McCaig AM, Carter-Brzezinski LJ,
Wheadon H, Leach MT, Le Ster K, Berthou C, Durieu E, Oumata N,
Galons H, et al: Inhibition of NF-κB-mediated signaling by the
cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli
to induce apoptosis in chronic lymphocytic leukemia cells. Clin
Cancer Res. 19:2393–2405. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wu X, Xu W, Feng X, He Y, Liu X, Gao Y,
Yang S, Shao Z, Yang C and Ye Z: TNF-a mediated inflammatory
macrophage polarization contributes to the pathogenesis of
steroid-induced osteonecrosis in mice. Int J Immunopathol
Pharmacol. 28:351–361. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schulz U, Munker R, Ertl B, Holler E and
Kolb HJ: Different types of human leukemias express the message for
TNF-alpha and interleukin-10. Eur J Med Res. 6:359–363.
2001.PubMed/NCBI
|
|
37
|
Aggarwal BB, Shishodia S, Ashikawa K and
Bharti AC: The role of TNF and its family members in inflammation
and cancer: lessons from gene deletion. Curr Drug Targets Inflamm
Allergy. 1:327–41. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang HQ, Li DL, Lu YJ, Cui XX, Zhou XF,
Lin WP, Conney AH, Zhang K, Du ZY and Zheng X: Anticancer activity
of Acanthopanax trifoliatus (L) Merr extracts is associated with
inhibition of NF-kB activity and decreased Erk1/2 and Akt
phosphorylation. Asian Pac J Cancer Prev. 15:9341–9346. 2014.
View Article : Google Scholar : PubMed/NCBI
|
